Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.sequent.in | |
Market Cap | 1,789.93 Cr. | |
Enterprise Value(EV) | 2,130.48 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -0.71 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-12 |
Industry PE | 31.87 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 25.09 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 2.86 | Calculated using Price: 71.76 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 24.94 Cr. | 249,433,495 Shares |
FaceValue | 2 | |
Company Profile | ||
Sequent Scientific earlier known as P I Drugs & Pharmaceuticals is an integrated pharmaceutical company. Hon'ble High Court of Bombay approved the Scheme of Amalgamation of company with P I Drugs & Pharmaceuticals Ltd. Pursuant to the Scheme of Amalgamation as approved by the Honourable High Court Bombay vide its order dated June 16, 2009 Company made requisite application to the Registrar of Companies Mumbai for change of its name from PI Drugs & Pharmaceuticals Ltd. to Sequent Scientific Ltd. Accordingly Registrar of Companies approved the application and issued fresh Certificate of Incorporation consequent upon change in name dated October 27, 2009 and with effect from the date the name of Company changed to Sequent Scientific Ltd. |
1 Day |
|
-2.57% |
1 Week |
|
-1.44% |
1 Month |
|
+7.51% |
3 Month |
|
-13.75% |
6 Month |
|
-32.75% |
1 Year |
|
-48.54% |
2 Year |
|
-70.88% |
5 Year |
|
-10.86% |
10 Year |
|
+184.42% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -201.83 | -28.10 | -3.35 | -1.74 | 54.15 | 8.63 | 12.06 | 15.00 | 6.60 | |
Return on Capital Employed (%) | -16.09 | 6.93 | 2.72 | 0.87 | 41.28 | 9.24 | 12.59 | 16.24 | 7.06 | |
Return on Assets (%) | -18.19 | -1.52 | -1.33 | -0.95 | 26.54 | 4.14 | 5.73 | 7.19 | 3.09 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 57 | 91 | 946 | 977 | 648 | 707 | 687 | 728 | 692 | 738 | |
Non Curr. Liab. | 159 | 278 | 300 | 246 | 227 | 215 | 216 | 154 | 199 | 175 | |
Curr. Liab. | 405 | 406 | 290 | 664 | 431 | 440 | 515 | 513 | 537 | 499 | |
Minority Int. | 5 | 147 | 2 | 17 | 37 | 40 | 45 | 49 | 48 | 44 | |
Equity & Liab. | 626 | 922 | 1,538 | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,477 | 1,456 | |
Non Curr. Assets | 360 | 612 | 1,047 | 1,176 | 805 | 796 | 739 | 676 | 665 | 685 | |
Curr. Assets | 266 | 310 | 491 | 728 | 538 | 606 | 724 | 767 | 812 | 771 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 626 | 922 | 1,538 | 1,904 | 1,343 | 1,402 | 1,463 | 1,443 | 1,477 | 1,456 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 455 | 465 | 625 | 684 | 1,031 | 1,039 | 1,179 | 1,362 | 1,413 | 1,438 | |
Other Income | 4 | 10 | 14 | 11 | 17 | 9 | 10 | 10 | 11 | 8 | |
Total Income | 459 | 475 | 639 | 695 | 1,048 | 1,048 | 1,189 | 1,372 | 1,424 | 1,446 | |
Total Expenditure | -439 | -445 | -568 | -643 | -919 | -914 | -1,009 | -1,152 | -1,303 | -1,389 | |
PBIDT | 21 | 30 | 71 | 52 | 129 | 134 | 180 | 220 | 120 | 57 | |
Interest | -39 | -44 | -39 | -28 | -40 | -33 | -36 | -24 | -16 | -31 | |
Depreciation | -33 | -33 | -46 | -40 | -53 | -42 | -51 | -51 | -51 | -52 | |
Taxation | -1 | -3 | -3 | 0 | -13 | -2 | -12 | -32 | -8 | 10 | |
Exceptional Items | -59 | 38 | 409 | -9 | -3 | ||||||
PAT | -110 | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -19 | |
Minority Interest | 1 | -2 | 3 | -9 | -8 | -12 | -9 | -4 | 1 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -110 | -11 | -18 | -14 | 422 | 49 | 70 | 95 | 41 | -18 | |
Adjusted EPS | -8 | -1 | -1 | -1 | 17 | 2 | 3 | 4 | 2 | -1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -4 | -45 | -24 | 0 | -7 | 45 | 116 | 115 | 115 | 31 | |
Cash Fr. Inv. | -55 | -80 | -155 | -316 | -116 | 7 | -68 | -72 | 10 | -96 | |
Cash Fr. Finan. | 35 | 146 | 179 | 309 | 147 | -57 | -20 | -43 | -139 | 67 | |
Net Change | -24 | 21 | 1 | -7 | 24 | -5 | 28 | 0 | -14 | 2 | |
Cash & Cash Eqvt | 3 | 23 | 22 | 20 | 44 | 40 | 68 | 68 | 54 | 58 |
Wed, 08 Mar 2023
Announcement under Regulation 30 (LODR)-Updates on Acquisition We refer to our announcement on November 07 2022 regarding acquisition of 100% stake in Tineta Pharma Private limited (Tineta) by the Company it is hereby informed that the transaction contemplated under the Share Purchase Agreement has not been materialized. Therefore the Company will not acquire Tineta and the Share Purchase Agreement entered by the Company with Tineta and its Promoters on November 07 2022 stands terminated. |
Tue, 21 Feb 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the Earnings Call Transcript pertaining to the Unaudited Financial Results of the Company for quarter and nine months ended December 31 2022. |
Thu, 16 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to the provision of Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed copies of advertisement published on February 16 2023 in Financial Express and Mumbai Lakshadeep newspaper providing Extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2022. |
Fri, 24 Mar 2023 |
|
|
|
|
|